State of the Art: Concise ReviewDevelopment of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
Under an Elsevier user license
open archive
Key Words:
PI3K/AKT/mTOR pathway
Personalized medicine
Non–small cell lung cancer
Cited by (0)
Disclosure: The author has received research funding from Merck, Astra Zeneca, Pfizer, Bayer, and Astellas. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation.
Copyright © 2012 International Association for the Study of Lung Cancer. All rights reserved.